


BIORANKINGS

ALTERNATIVE STATISTICS CALCULATED FROM KERYX DATA

The BioRankings method showed the data was too close to warrant a guaranteed pass or fail for Keryx's Sulodexide

Clinical Trial

Keryx's lead compound under development, Sulodexide, was a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy. Sulodexide was in a pivotal Phase III /Phase IV clinical program under a Special Protocol Assessment with the FDA.



BioRankings performed a sensitivity analysis of previously published Sulodexide data used to design Keryx's study. By varying the response-to-treatment rates (see histograms) slightly, we showed that the prior data quickly became highly non-significant.

Conclusions

Our sensitivity analysis calculations could not be used to definitively predict success or failure of the trial. However, this analysis did raise a red flag about the possibility of this trial not being significant.

In March 2008, Keryx reported that Sulodexide did not achieve statistical significance.



BIORANKINGS

William D. Shannon, PhD (314) 704-8725